Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

DNA methylation instability as a biomarker to predict resistance or progression to advanced disease Phase following tyrosine kinase inhibitor therapy in chronic myeloid leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

YMYael MorgensternOAOyeronke AyansolaDPDanielle Pyne

Discussion

Loading...

Member takes

Overview

Analysis reveals DNA methylation instability predicts treatment response and progression in chronic myeloid leukemia, indicating its role as a potential biomarker.

Key Points

  • Elevated biomarker levels predict disease progression during tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
  • Progression-free survival at four years was notably 94% among patients, highlighting effective treatment outcomes.
  • Utilizing DNA methylation profiling, the study assessed epigenetic changes using paired bone marrow samples for comprehensive analysis.
  • Findings indicate the potential of DNA methylation instability as a significant prognostic biomarker in clinical settings.

Cite This Study

Morgenstern et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d4fehttps://doi.org/10.1182/blood-2025-7274
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Multimodal epigenetic microarray classifies AML, MDS and controls using peripheral blood2025
  2. 2Unravelling the epigenetic drivers of chip – MDS/CMML – AML progression through novel methylation-sensitive regulatory elements2025
  3. 3MicroRNAs as prognostic and predictive biomarkers among chronic myeloid leukemia patients in Addis Ababa, Ethiopia2025 · 1 citations
  4. 4Non-invasive detection and classification of lymphoma via cell-free DNA methylation profiling2025
  5. 5Prognostic relevance of epigenetic regulation of drug pharmacology and myeloid genes in pediatric AML2025